Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Neurocrine Biosciences, Inc. (NBIX) to present at Jefferies London Healthcare Conference on November 14, 2023. CEO Kevin Gorman and management team to present. Webcast available on company's website. Replay also accessible.

SAN DIEGO, Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies London Healthcare Conference on Tuesday November 14, 2023 at 3:00 p.m. Greenwich Mean Time (10:00 a.m. Eastern Time) in London. Kevin Gorman, Chief Executive Officer, and additional members of Neurocrine management will present at the conference.

The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, Parkinson's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (formerly Twitter) and Facebook. (*in collaboration with AbbVie)

NEUROCRINE BIOSCIENCES and NEUROCRINE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-jefferies-london-healthcare-conference-301982290.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

What is the event Neurocrine Biosciences, Inc. (NBIX) will be presenting at?

Neurocrine Biosciences, Inc. (NBIX) will be presenting at the Jefferies London Healthcare Conference on November 14, 2023.

Who will be presenting at the conference?

CEO Kevin Gorman and additional members of Neurocrine management will be presenting at the conference.

Where can the webcast of the presentation be accessed?

The webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.